Drug General Information (ID: DDIKPVACU4)
Drug Name			Moexipril		Drug Info		Drospirenone		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Antihypertensive Agents				Contraceptive Agents
Structure

Mechanism of Moexipril-Drospirenone Interaction (Severity Level: Moderate)
Increased risk of hyperkalemia Click to Show/Hide Mechanism Graph
Drug Name		Moexipril				Drospirenone
Mechanism		Hyperkalemia				Hyperkalemia
Key Mechanism Factor 1
		Factor Name		Hyperkalemia
		Factor Description		Hyperkalemia is a condition in which the level of potassium in the blood is higher than normal. While mild cases may not produce symptoms, severe hyperkalemia can lead to fatal arrhythmias if left untreated.
Mechanism Description		Increased risk of hyperkalemia by the combination of Moexipril and Drospirenone

Recommended Action
Management		Serum potassium levels should be checked regularly during concomitant therapy with drospirenone and other agents that can increase serum potassium. Particular caution is warranted in patients with renal impairment, diabetes, old age, severe or worsening heart failure, or dehydration. Patients should be advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.

References
1	Product Information. Yasmin (drospirenone-ethinyl estradiol) Berlex Laboratories, Richmond, CA.
2	Ponce SP, Jennings AE, Madias NE, Harrington JT "Drug-induced hyperkalemia." Medicine (Baltimore) 64 (1985): 357-70. [PMID: 2865667]